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Tachyarrhythmias may be secondary to a generalised
process such as thyrotoxicosis, drug intoxication, or
electrolyte imbalance; it may be an expression of cardiac
failure or result from a specific process within the heart
(primary arrhythmias). The mechanism of such primary
arrhythmias may be mainly anatomically based, such as
occurs with accessory pathways and ventricular aneurysm,
or functional, reflecting, for example, the effects of
increased sensitivity of specific areas within the heart to
the normal fluctuation in circulating catecholamines. It
is in the area of primary arrhythmias that the physician
has traditionally tried varieties of drugs, often on a
somewhat empirical basis with variable (often unknown)
degrees of success. The development of safe open-heart
surgery combined with a better understanding of the
mechanisms of supraventricular tachycardias in the
Wolff-Parkinson-White (WPW) syndrome inspired Sealy
in 1968 to undertake isolation and division of accessory
pathways. The resultant freedom from recurrent episodes
of tachycardia without the use of drugs associated with
the loss of the delta wave, the hallmark of WPW,
ushered in the era of anti-arrhythmic surgery.
The role of pharmacological therapy for chronic
recurrent tachyarrhythmias is basically prophylactic and
based on the proposition that the effective agent will
either suppress the initiating process or prevent per-
petuation of the arrhythmia. Non-pharmacological
methods act either by preventing the arrhythmia by
removing the basic anatomical substrate (thus offering
the possibility of a cure), or by interacting with the
process once the arrhythmia has developed, a rescue
action as typified by the implantable defibrillator.
Specific alteration of a relatively large and localised
arrhythmogenic environment has been promised by left
stellate ganglion resection in patients with recurrent
syncope and prolonged QT syndromes.
Pharmacological therapy has been with us for a long
time, is by and large non-invasive and is freely available.
It is what we have been used to. Among the important
problems with pharmacological therapy is the fact that it
acts via systemic drug delivery for a highly localised
problem. Generalised side-effects are thus a frequent
accompaniment. An example of this is the excess of 17%
incidence of serious systemic side-effects requiring
cessation of treatment for amiodarone therapy for impor-
tant, usually'life-threateningarrhythmias. 1 Most potent
anti-arrhythmic drugs are aninotropic and are frequently
dangerous when given to patients with concomitant
mechanical cardiac dysfunction. The results of the recent
CAST study2 highlighted the danger of empirical anti-
arrhythmic therapy for patients with varying degrees of
ventricular ectopy and non-sustained ventricular tachy-
cardia after myocardial infarction. In this study, the use
of type IC drugs, i.e. flecainide and encainide, was
associated with a highe-r mortality than placebo. This
high mortality probably related to their propensity to
produce arrhythmias as well as the low mortality from
the ventricular arrhythmias being treated. Indeed, it is
only when drug therapy is guided by repeated challenge
by invasive programmed stimulation of the ventricle
that the incidence of recurrent ventricular tachycardia
has been shown to be favourably affected.
It is difficult to be sure of the costs of each prescription
for anti-arrhythmic therapy. Many potent anti-arrhythmic
drugs are extremely expensive when given in a dose
likely to be effective for major chronic recurrent arrhyth-
mias such as ventricular tachycardia or atrial fibrillation
with rapid ventricular response in patients with a func-
tioning accessory pathway. On the other hand, correct
utilisation of, for example, ~-blocking drugs or digitalis
can be highly cost-effective.
Non-pharmacological methods of therapy include
ablation of accessory pathways, resection of ventricular
aneurysms, excision of automatic, usually atrial, foci,
physical ablation or modification of the atrioventricular
node and the use of devices such as the anti-tachycardia
pacemakers and implantable defibrillators. There has
been outstanding success with ablative techniques,
particularly to accessory pathways, and with implantable
defibrillators. Ablation of accessory pathways may be
surgical or may utilise transcatheter techniques. The
success rate for surgical ablation in a number of centres
is so high and the mortality and morbidity so low, that
the indications for surgery have been broadened virtually-
to include all symptomatic patients with the WPW
,syndrome. Indeed, in the face of these results, it is
becoming more difficult to justify a pharmacological
approach. The choice will of course widen further once
transcatheter ablative techniques have been perfected.
Such techniques will offer an attractive alternative to
life-long pharmacological therapy.
In this issue (p. 583) Scott Millar and colleagues
report the current status of surgery for accessory path-
ways at Groote Schuur Hospital. Their results are similar
to those reported earlier from other institutions, who
have now attained near 100% success with extremely low
morbidity and mortality.3 The authors have clearly
defmed the problem areas and the steps necessary to
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overcome them. We are encouraged that these necessary
steps are well within their capabilities. The excellent
status of their successful cases and their clear and
extremely encouraging commitment to this problem
augur well for future results. We look forward to these
and similar approaches in other specialised institutions.
On a par with the success of WPW surgery has been
that obtained with implantable automatic cardioverter-
defibrillators for recurrent ventricular fibrillation and
haemodynamically unstable ventricular tachycardia. The
life survival figures for high-risk patients with life-
threatening arrhythmias receiving these devices is greater
than 98% at 1 year and 94% at 5 years in two major
series4,5 and the number of implants is therefore growing
exponentially. Newer devices are extremely sophisticated,
not only capable of diagnosing and automatically treating
ventricular fibrillation or ventricular tachycardia, but
also offering various forms of anti-tachycardia pacing,
cardioversion and cardiac pacing in a programmable
sequence. Seven such devices have been implanted in
South Africa to date, some via the transvenous route.
We await the long-term results 'of local experience.
Transcatheter ablation of the atrioventricular node with
pacemaker implantation for drug-resistant supraventricu-
lar tachycardias has to my knowledge been performed in
3 centres in South Mrica, with. reasonable results. Inter-
nationally the results of such transcatheter ablative
techniques are improving both in regard to efficacy and
lack of morbidity and mortality. Much of this relates to
technological advances in energy delivery systems.
Choosing appropriate therapy for individual patients
at a particular point in time is an ongoing challenge. In
the field of primary recurrent tachyarrhythmias there is
no doubt that there will be a growing role .for non-
pharmacological methods. Pari passu with this has been
the realisation that accurate diagnosis and understanding
of the natural history of specific arrhythmias is essential
for such choice to be rational and, as the CAST study
has shown us, safe. Currently non-pharmacological
methods are largely reserved for patients in whom drug
. therapy has either failed or is unacceptable. In this era
of technological advance we can·look forward to more
refined and specific forms of non-pharmacological
therapy for patients with recurrent tachyarrhythmias
and consequently freedom from drug side-effects.
Ablative techniques offer, at last, a prospect of cure.
I. W. P. Obel
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Alpha-adrenergic agonists in anaesthesia
and ana~gesia
Alpha-2-adrenergic receptors are present in the central
nervous system in both presynaptic and postsynaptic
locations, I and there has recently been substantial interest
in the anaesthetic and analgesic properties of 0!2-adre-
nergic agonists. Activation of the 0!2-adrenergic receptors
produces many physiological effects, including anxiolysis,
sedation, decreased salivary secretions, bradycardia,
lowered blood pressure (reduced sympathetic flow),
hypothermia, and mydriasis.2 Given their desirable phy-
siological profIle, 0!2-agonists could be useful anaesthetic
and analgesic adjuvants. Surgical procedures, endotra-
cheal intubation, and anaesthesia are stressful. They
may induce potentially harmful' reactions, such as
increases in the secretion of catecholamines and other
stress hormones, and increases in heart rate and blood
pressure.3Effective attenuation of the sympatho-adrenal
stress responses is an important goal in modern anaesthe-
sia, especially in patients with hypertension and coronary
artery disease. The 0!2-agoniSts may play an important
role in this regard.
The 0!2-agonists include drugs such as clonidine,
medetomidine, and azepexole. Clonidine has a longer
plasma elimination half-life (7,7 hours) compared with
dexmedetomidine (2,3 hours).3 It is 10 - 100 times less
selective for the 0!2-adrenergic receptor than dexmede-
tomidine, and is known to have a ceiling effect that
limits its anaesthetic action. l This may be due to its O!l-
agonist properties, which manifest themselves at·
higher doses. Medetomidine is a l:-l racemic mixture of
optical isomers of which the d-isomer, dexmedetomidine,
is pharmacologically active;3 It is a more effectiv~ O!r
agonist than clonidine in most pharmacological models
tested so far. Another selective 0!2-agOniSt, azepexole,
has similar anaesthetic properties to dexmedetomidine.2
The advantages of 0!2-agonists include lack of major
respiratory depression and addiction, and lack of other
opioid side-effects, such as nausea, vomiting, or pruritus.4
Disadvantages include hypotension, bradycardia, and a
drop in cardiac output. The reduction in the activities of
the sympathetic nervous system can be reversed by 0!2-
antagonists (idazoxan, atipamezole, and yohimbine).4
They decrease heart rate by direct cardiac as well as
central mechanisms, and may decrease velocity through
the cardiac conduction system. 5 Caution is needed in
pa.tients with pre-exIstmg conduction disturbances.
!IfPotension can occur due to a brainstem-mediated
Ulbibition of sympathetic and enhancement of para-
sY'mpathetic activity.' The dose of 0!2-agOniSt must there-
f0te be ~efully assessed. With clonidine (at high doses),
th-ls lowering of blood pressure is balanced by its direct
vasoconstrictor action on peripheral blood vessels. In
hUmans (unlike animal studies), serum glucose, cortisol
and anerial oxyhaemoglobin saturation seem unaffected
by 0!2-agonists after chronic systemic and acute epidural
administration,6 although acute systemic administration
of clonidine may reduce serum glucose and cortisol
le\\els. 7
'The 0!2-agonists have been used as premedicants. Oral
clcmidine and intravenous dexmedetomidine resulted in
a Significant reduction in fear and anxiety experienced.3,8,9
Dryness of the mouth and sedation also occurred. Given
as premedicants, 0!2-agonists have been found to reduce
th~ sleep dose of induction agents needed (e.g. thiopen-
WIle,3 methohexitone9).
By inhibiting sympathetic transmitter release, 0!2-
ag(>nists reduce catecholamine levels and improve haemo-
dYnamic stability during the induction and maintenance
of anaesthesia. 1,3 They also reduce the amount of inhala-
tiohal anaesthetic agents needed by acting on presynaptic
anli postsynaptic 0!2-adrenergic receptors in the central
neJ:vous system and inhibiting central noradrenaline
release.3 This is reflected by a lower MAC value. IO
Several investigators have proved 0!2-agonists to be
anaesthetic-sparing agents with hypnotic and analgesic
effects of their own. lO They augment the peri-operative
analgesia/anaesthesia produced by opioids,I,4 and opioid
dosage can thus be reduced. Dexmedetomidine can
induce skeletal muscle relaxation, and may be clinically
effective in preventing the muscle rigidity produced by
moderate to high doses of opioids.2
The 0!2-agOniSts effect cerebral vasoconstriction by
increasing cerebral vascular resistance due to stimulation
of postsynaptic 0!2-adrenergic receptors located in cere-
bral vessels. I They may thus be useful adjunct agents in
neurosurgery. Qonidine has been shown to decrease
cerebral blood flow in healthy human volunteers.9 Dex-
medetomidine (in dogs) causes significant reduction in
CBF without influencing the metabolic rate of oxygen. 10
The 0!2-agonists are also analgesics when given epidu-
rally and intrathecally. They block transmission of pain
information by activating presynaptic and postsynaptic
0!2-adrenergic receptors in the spinal cord, which inhibit
substance P release and dorsal horn neuron fIring respec-
tivdy.' Their lipid solubility and rapid absorption and
elin1ination in the cerebrospinal fluid limit rostral spread.
Epidural clonidine has an onset and duration of analgesia
similar to that of epidural fentanyl.' The duration of
analgesia may be prolonged by injection of large doses.'
It is slowly absorbed into the systemiccircu1ation (per-
haps due to slow release from epidural fat). Peak plasma
concentrations may not occur until more than 1 hour
after injection. 6 Clonidine's shon elimination half-life in
the cerebrospinal fluid (43 minutes) suggests that accumu-
latiiln is unlikely.6 Qonidine is preservative-free and
isotonic, with a pH of 4,0 - 4,5, making it suitable for
epiliural administration. Several animal studies have
sho'wo no direct neurotoxic effects."
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Epidural clonidine (600 J.Lg or more) is effective for
acute postoperative pain.' The most common side-effect
is hypotension. This occurs mainly from inhibition of
sympathetic nervous activity in the spinal cord. It is
more likely to occur following intrathecal administration
in patients with pre-existing hypenension or with hypo-
volaemia.' Because clonidine may increase blood pressure
by a peripheral action, hypotensiori is again lessened by
increasing plasma concentrations.6
When 0!2-agOniSts are combined with opioids (clonidine
and morphine) either epidurally or intrathecally, a shift
. . , ft 12 13of the 0PIOId dose-response curve to the le occurs. '
The combination produces greater analgesia than either
alone, thereby reducing dose requirements, and delaying
the onset of tolerance. l2,13 It has been found that low
doses of both clonidine and morphine do not reduce
wide dynamic range neuronal activity (in cats), whereas
the combination of the two produced significant reduc-
tions. 14 This is borne out clinically as sub-analgesic
concentrations of clonidine and morphine will potentiate
one another. Combinations of 0!2-llg0niSts, opioids, and
local anaesthetic agents l2,15 (e.g. clonidine, fentanyl,
bupivacaine) are now used for peri-operative anaesthesia
and analgesia. Pain is then inhibited by three different
mechanisms, resulting in a decrease in the dose of 0!2-
agonist, opioid and local anaesthetic agent needed. 16
With the manufacrure of microcatheters (28-32-gauge),
intermittent or continuous intrathecal delivery of these
combinations is now possibleY
The 0!2-agOniSts have been found to suppress shivering
after epidurals with local anaesthetic agents. 18 Intra-
venous clonidine (150 J.Lg) has been found to reduce
postoperative oxygen consumption:19 Epidural clonidine
(100 - 900 J.Lg) has been found to be effective in treating
deafferentation or neurogenic pain in the cancer patient.6
Effective analgesia can also be produced when tolerance
to opioids has developed and epidural clonidine/mor-
phine infusions have been successfully administered to
cancer patients at home for up to 5 months.6 Epidural
clonidine has been successful in treating the pain in
arachnoiditis and proctalgia fugax, and also in treating
deafferentation pain following spinal cord injuries or
peripheral nerve injuries.20 (Oral clonidine has long
been used in the treatment of migraine.) In conclusion,
the 0!2-agOniSts have propenies of great potential benefIt
to anaesthesia and pain control. They are already widely
used as veterinary sedative-analges~cs.21 However, their
advantages and limitations require further defInition.
The identifIcation of subpopulations of 0!2-adrenergic .
receptors may provide new opponunities for the deve-
lopment of subtype-selective pharmacological agents with
more specilic therapeutic actions.
E. A. Shipton
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overcome them. We are encouraged that these necessary
steps are well within their capabilities. The excellent
status of their successful cases and their clear and
extremely encouraging commitment to this problem
augur well for future results. We look forward to these
and similar approaches in other specialised institutions.
On a par with the success of WPW surgery has been
that obtained with implantable automatic cardioverter-
defibrillators for recurrent ventricular fibrillation and
haemodynamically unstable ventricular tachycardia. The
life survival figures for high-risk patients with' life-
threatening arrhythmias receiving these devices is greater
than 98% at I year and 94% at 5 years in two major
series4,5 and the number of implants is therefore growing
exponentially. Newer devices are extremely sophisticated,
not only capable of diagnosing and automatically treating
ventricular fibrillation or ventricular tachycardia, but
also offering various forms of anti-tachycardia pacing,
cardioversion and cardiac pacing in a programmable
sequence. Seven such devices have been implanted in
South Africa to date, some via the transvenous route.
We await the long-term results 'of local experience.'
Transcatheter ablation of the atrioventricular node with
pacemaker implantation for drug-resistant supraventricu-
lar tachycardias has to my knowledge been performed in
3 centres in South Africa, with. reasonable results. Inter-
nationally the results of such transcatheter ablative
techniques are improving both in regard to efficacy and
lack of morbidity and mortality. Much of this relates to
technological advances in energy delivery systems.
Choosing appropriate therapy for individual patients
at a particular point in time is an ongoing challenge. In
the field of primary recurrent tachyarrhythmias there is
no doubt that there will be a growing role .for non-
pharmacological methods. Pari passu with this has been
the realisation that accurate diagnosis and understanding
of the natural history of specific arrhythmias is essential
for such choice to be rational and, as the CAST study
has shown us, safe. Currently non-pharmacological
methods are largely reserved for patients in whom drug
. therapy has either failed or is unacceptable. In this era
of technological advance we can ·look forward to more
refined and specific forms of non~pharmacological
therapy for patients with recurrent tachyarrhythmias
and consequently freedom from drug side-effects.
Ablative techniques offer, at last, a prospect of cure.
I. W. P. Obel
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Alpha-adrenergic agonists in anaesthesia
and analgesia
Alpha-2-adrenergic receptors are present in the central
nervous system in both presynaptic and postsynaptic
locations, 1 and there has recently been substantial interest
in the anaesthetic and analgesic properties of cxz-adre-
nergic agonists. Activation of the cxz-adrenergic receptors
produces many physiological effects, including anxiolysis,
sedation, decreased salivary secretions, bradycardia,
lowered blood pressure (reduced sympathetic flow),
hypothermia, and mydriasis.z Given their desirable phy-
siological profile, cxz-agonists could be useful anaesthetic
and analgesic adjuvants. Surgical procedures, endotra-
cheal intubation, and anaesthesia are stressful. They
may induce potentially harmful' reactions, such as
increases in the secretion of catecholamines and other
stress hormones, and increases in heart rate and blood
pressure.3Effective attenuation of the sympatho-adrenal
stress responses is an important goal in modern anaesthe-
sia, especially inpatients with hypertension and coronary
artery disease. The cxz-agonists may play an important
role in this regard.
The cxz-agonists include drugs such as clonidine,
medetomidine, and azepexole. Clonidine has a longer
plasma elimination half-life (7,7 hours) compared with
dexmedetomidine (2,3 hours).3 It is 10 - 100 times less
selective for the cxz-adrenergic receptor than dexmede-
tomidine, and is known to have a ceiling effect that
limits its anaesthetic action.! This may be due to it's cx!-
agonist properties, which manifest themselves at
higher doses. Medetomidine is a I: I racemic mixture of
optical isomers of which the d-isomer, dexmedetomidine,
is pharmacologically active;3 It is a more effectiv~ cxz-
agonist than clonidine in most pharmacological models
tested so far. Another selective cxz-agonist, azepexole,
has similar anaesthetic properties to dexmedetomidine.z
The advantages of cxz-agonists include lack of major
respiratory depression and addiction, and lack of other
opioid side-effecrs, such as nausea, vomiting, or pruritus.4
Disadvantages include hypotension, bradycardia, and a
drop in cardiac output. The reduction in the activities of
the sympathetic nervous system can be reversed by cxz-
antagonists (idazoxan, atipamezole, and yohimbine).4
They decrease heart rate by direct cardiac as well as
central mechanisms, and may decrease velocity through
the cardiac conduction system.5 Caution is needed in
pa.tients with pre-exlstmg conduction disturbances.
Hypotension can occur due to a brainstem-mediated
inhibition of sympathetic and enhancement of para-
sympathetic activity.5 The dose of 0'2-agOnist must there-
fote be c~efully assessed. With clonidine (at high doses),
this lowering of blood pressure is balanced by its direct
vasoconstrictor action on peripheral blood vessels. In
humans (unlike animal studies), serum glucose, cortisol
and arterial oxyhaemoglobin saturation seem unaffected
by 0'2-agonists after chronic systemic and acute epidural
administration,6 although acute systemic administration
of clonidine may reduce serum glucose and cortisol
levels. 7
The 0'2-agOnists have been used as premedicants. Oral
clonidine and intravenous dexmedetomidine resulted in
a significant reduction in fear and anxiety experienced.3,8,9
Dryness of the mouth and sedation also occurred. Given
as premedicants, 0'2-agonists have been found to reduce
the sleep dose of induction agents needed (e.g. thiopen-
tone,3 methohexitone9).
By inhibiting sympathetic transmitter release, 0'2-
agonists reduce catecholamine levels and improve haemo-
dynamic stability during the induction and maintenance
of anaesthesia. 1,3 They also reduce the amount of inhala-
tional anaesthetic agents needed by acting on presynaptic
and postsynaptic 0'2-adrenergic receptors in the central
nervous system and inhibiting central noradrenaline
release.3 This is reflected by a lower MAC value. IQ
Several investigators have proved 0'2-agonists to be
anaesthetic-sparing agents with hypnotic and analgesic
effects of their own. IQ They augment the peri-operative
analgesia/anaesthesia produced by opioids,I,4 and opioid
dosage can thus be reduced. Dexmedetomidine can
induce skeletal muscle relaxation, and may be clinically
effective in preventing the muscle rigidity produced by
moderate to high doses of opioids.2
The 0'2-agOnists effect cerebral vasoconstriction by
increasing cerebral vascular resistance due to stimulation
of postsynaptic 0'2-adrenergic receptors located in cere-
bral vessels. I They may thus be useful adjunct agents in
neurosurgery. Clonidine has been shown to decrease
cerebral blood flow in healthy human volunteers.9 Dex-
medetomidine (in dogs) causes significant reduction in
CBF without influencing the metabolic rate of oxygen. IQ
The 0'2-agonists are also analgesics when given epidu-
rally and intrathecally. They block transmission of pain
information by activating presynaptic and postsynaptic
Q:2-adrenergic receptors in the spinal cord, which inhibit
substance P release and dorsal horn neuron fIring respec-
tively.5 Their lipid solubility and rapid absorption and
elimination in the cerebrospinal fluid limit rostral spread.
Epidural clonidine has an onset and duration of analgesia
similar to that of epidural fentanyl.5 The duration of
analgesia may be prolonged by injection of large doses.5
It is slowly absorbed into the systemic circulation (per-
haps due to slow release from epidural fat). Peak plasma
concentrations may not occur until more than 1 hour
after injection.6 Clonidine's short elimination half-life in
the cerebrospinal fluid (43 minutes) suggests that accumu-
lation is unlikely.6 Clonidine is preservative-free and
isotonic, with a pH of 4,0 - 4,5, making it suitable for
epidural administration. Several animal studies have
shown no direct neurotoxic effects. ll
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Epidural clonidine (600 J.lg or more) is effective for
acute postoperative pain.5The most common side-effect
is hypotension. This occurs mainly from inhibition of
sympathetic nervous activity in the spinal cord. It is
more likely to occur following intrathecal administration
in patients with pre-existing hypertension or with hypo-
volaemia.5Because clonidine may increase blood pressure
by a peripheral action, hypotensiOli is again lessened by
increasing plasma concentrations.6
When 0'2-agOnists are combined with opioids (clonidine
and morphine) either epidurally Qr intrathecally, a shift
• • J 12 13
of the OPIOld dose-response curve to the left occurs. '
The combination produces greater analgesia than either
alone, thereby reducing dose requirements, and delaying
the onset of tolerance. 12,13 It has been found that low
doses of both clonidine and morphine do not reduce
wide dynamic range neuronal activity (in cats), whereas
the combination of the two produced significant reduc-
tions. I4 This is borne out clinically as sub-analgesic
concentrations of clonidine and morphine will potentiate
one another. Combinations of 0'2-3g0nists, opioids, and
local anaesthetic agents l2,I5 (e.g. clonidine, fentanyl,
bupivacaine) are now used for peri-operative anaesthesia
and analgesia. Pain is then inhibited by three different
mechanisms, resulting in a decrease in the dose of 0'2-
agonist, opioid and local anaesthetic agent needed}6
With the manufacture of microcatheters (28-32-gauge),
intermittent or continuous intrathecal delivery of these
combinations is now possible.I 7
The 0'2-agOnists have been found to suppress shivering
after epidurals with local anaesthetic agents. IS Intra-
venous clonidine (150 J.lg) has been found to reduce
postoperative oxygen consumption:19 Epidural clonidine
(100 - 900 J.lg) has been found to be effective in treating
deafferentation or neurogenic pain in the cancer patient.6
Effective analgesia can also be produced when tolerance
to opioids has developed and epidural clonidine/mor-
phine infusions have been successfully administered to
cancer patients at home for up to 5 months.6 Epidural
clonidine has been successful in treating the pain in
arachnoiditis and proctalgia fugax, and also in treating
deafferentation pain following spinal cord injuries or
peripheral nerve injuries.2Q (Oral clonidine has long
been used in the treatment of migraine.) In conclusion,
the 0'2-agonists have properties of great potential benefIt
to anaesthesia and pain control. They are already widely
used as veterinary sedative-analges.ics.21 However, their
advantages and limitations require further defInition.
The identifIcation of subpopulations of 0'2-adrenergic -
receptors may provide new opportunities for the deve-
lopment of subtype-selective pharmacological agents with
more specifIc therapeutic actions.
E. A. Shipton
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The high price of becoming a doctor
By its very nature, medical education is an expensive
business which involves taking the cream of school
leavers and putting them through a highly intensive
syllabus for 6 years, during which time they are almost
totally economically non-productive. Added to the cost
of tuition is the cost of accommodation, food and trans-
port as well as all the other expenses which are part and
parcel of everyday living. However, as a paper by
Colbom in this issue of the SAMJ shows (p. 616), what
has always been a heavy financial burden is now
becoming virtually unsupportable except by the very
affluent. The average indebtedness of 5th and 6th year
students at vcr amounted to approximately R37000
each, of which in the region of R2l500 will have to be
repaid in cash, and the balance by various service strings
which may be attached to the bursary. Not only does
this have serious financial implications for the individuals
involved, and their families, but it also has a direct
effect on the kind of students who take up medicine,
and the kind of doctors that they become. Anyone who
qualifies in medicine saddled with an enormous debt
will have only one thing in mind at the start of his or
her professional career, and that is to make as much
money as soon as possible. However, to do so is not
easy, given the low salaries customarily paid to newly-
qualified doctors, and whether such motivation is
desirable for someone starting out on a 'professional
career is highly debatable.
As the paper by Colbom points out, the pattern of
those applying for the M.B. Ch.B. course at VCT is
changing, and presumably the same is happening at
other universities. White applicants are fewer, and black
applicants on the increase. In acountry which is currently
undergoing fundamental changes, and in which there
have been far too few black doctors, this is a healthy
trend, but whether those from the less affluent sector of
the population will be able to shoulder the crippling cost
of their medical education is open to question.
In an ideal world, anyone who possesses the necessary
qualities to become a doctor, which should include a
strong sense of vocation, should be enabled to pursue
their medical studies without completing them in a
virtually bankrupt state. The burden is now too heavy.
Who will help to lift it?
N. C. Lee
